DLPIC
SRPT icon

Davide Leone & Partners Investment Company’s Sarepta Therapeutics SRPT Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,775
Closed -$729K – 103
2021
Q1 		$729K Buy
+9,775
New +$902K 0.09% 96

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Davide Leone & Partners Investment Company's SRPT Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 9,775 shares — an estimated $729K sold.

Davide Leone & Partners Investment Company first reported a position in SRPT in Q1 2021 and held it in 1 quarter. The position peaked at $729K in Q1 2021. 331 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 9,775 Sarepta Therapeutics shares in Q2 2021, an estimated $729K.
  • Davide Leone & Partners Investment Company first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 1 quarter.
  • Davide Leone & Partners Investment Company's Sarepta Therapeutics position peaked at $729K in Q1 2021.
  • 331 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.